Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 47Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27fludarabine 26tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × AZD9833 × Gastrointestinal × Clear all
NCT04644068 2026-02-19

PETRA

AstraZeneca

Phase 1/2 Active not recruiting
702 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡